Denali Therapeutics (DNLI) Net Margin (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly Net Margin of 7841.59% for Q3 2023, down 478088.0% year-over-year from N/an in Q3 2022, and down 12676.92% quarter-over-quarter from 62.35% in Q2 2023.
Denali Therapeutics (DNLI) Net Margin (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Net Margin for 6 consecutive years, with 7841.59% the latest figure, recorded in Q3 2023.
- In Q3 2023, Net Margin fell 478088.0% year-over-year to 7841.59%; the TTM figure through Jun 2024 stood at 33567.56% (down 3352922.0% YoY), while the FY2023 annual figure was 43.94%, up 26634.0% from the prior year.
- Net Margin fell to 7841.59% in Q3 2023 per DNLI's latest filing, from 62.35% in the prior quarter.
- Across five years, Net Margin topped out at 77.3% in Q4 2020 and bottomed at 109226.92% in Q1 2020.
- Historically, Net Margin has averaged 7016.39% across 5 years, with a median of 927.28% in 2019.
- Annual changes were most pronounced in 2020 — Net Margin slumped 10829965 bps — and 2021, when it surged 10834279 bps.
- Denali Therapeutics' Net Margin stood at 3648.78% in 2019, then jumped by 102 bps to 77.3% in 2020, then sank by 300 bps to 154.69% in 2021, then plunged by 538 bps to 986.78% in 2022, then plunged by 695 bps to 7841.59% in 2023.
- Business Quant data shows DNLI's Net Margin at 7841.59% in Q3 2023, 62.35% in Q2 2023, and 320.93% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -3,622.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,622.45% |
| Sep 30, 2023 | -7,841.59% |
| Jun 30, 2023 | 62.35% |
| Mar 31, 2023 | -320.93% |
| Dec 31, 2022 | -986.78% |
| Sep 30, 2022 | -3,060.71% |
| Jun 30, 2022 | -112.03% |
| Mar 31, 2022 | -164.01% |
| Dec 31, 2021 | -154.69% |
| Sep 30, 2021 | -1,600.53% |
| Jun 30, 2021 | -404.61% |
| Mar 31, 2021 | -884.13% |
| Dec 31, 2020 | 77.30% |
| Sep 30, 2020 | -620.24% |
| Jun 30, 2020 | -1,011.15% |
| Mar 31, 2020 | -109,226.92% |
| Dec 31, 2019 | -3,648.78% |
| Sep 30, 2019 | -1,063.18% |
| Jun 30, 2019 | -1,423.55% |
| Mar 31, 2019 | -927.28% |